home / stock / opnt / opnt news

OPNT News and Press, Opiant Pharmaceuticals Inc. From 05/12/20

Stock Information
Company Name: Opiant Pharmaceuticals Inc.
Stock Symbol: OPNT
Market: NASDAQ
Menu
OPNT OPNT Quote OPNT Short OPNT News OPNT Articles OPNT Message Board
Get OPNT Alerts

News, Short Squeeze, Breakout and More Instantly...
OPNT - Opiant Pharmaceuticals Announces First Quarter 2020 Financial Results and Corporate Update

SANTA MONICA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March ...
OPNT - Opiant Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on Tuesday, May 12

SANTA MONICA, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the fir...

OPNT - Opiant Pharmaceuticals to Report Fourth Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, March 4

SANTA MONICA, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the four...

OPNT - Opiant inks collaboration deal to develop OPNT004 for acute cannabinoid overdose

Opiant Pharmaceuticals (NASDAQ: OPNT ) has signed a Letter of Intent with NIH's National Center for Advancing Translational Sciences (NCATS) to collaborate on the development of OPNT004 (drinabant) for the treatment of acute cannabinoid overdose (ACO). More news on: Opiant Pharmaceutical...
OPNT - Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose

SANTA MONICA, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it has signed a Letter of Intent with the Na...

OPNT - Opiant nabs second tranche of BARDA contract for nasal nalmefene

U.S. Health and Human Services unit BARDA has awarded the second tranche of its contract with Opiant Pharmaceuticals (NASDAQ: OPNT ), valued at ~$2.4M, to accelerate the development of nasal nalmefene for the potential treatment of opioid overdose. More news on: Opiant Pharmaceuticals, I...

OPNT - Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

SANTA MONICA, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it has been awarded the second tranche of ap...
OPNT - BioCorRx up 8% on encouraging data on opioid overdose candidate

Ultra-thinly traded nano cap BioCorRx ( OTCQB:BICX +7.7% ) is up, albeit on only 700 shares, in reaction to encouraging preclinical data on VDM-001, its candidate for the reversal of opioid overdose that it says is an alternative to naloxone. More news on: BioCorRx Inc., Aurobindo Phar...

OPNT - Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2019 Results - Earnings Call Transcript

Opiant Pharmaceuticals, Inc. (OPNT) Q3 2019 Earnings Conference Call November 12, 2019, 04:30 PM ET Company Participants Rahsaan Thompson - General Counsel Roger Crystal - CEO David O'Toole - CFO Conference Call Participants David Bautz - Zacks Presentation Operator...

OPNT - Opiant Pharmaceuticals EPS beats by $2.10, beats on revenue

Opiant Pharmaceuticals (NASDAQ: OPNT ): Q3 GAAP EPS of $1.97 beats by $2.10 . Revenue of $20.64M (+372.3% Y/Y) beats by $15.12M . Press Release More news on: Opiant Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

Previous 10 Next 10